Last reviewed · How we verify
NCT05109065
Peripheral Immune System in Individuals With Schizophrenia
trial testing SCID (Standardized Clinical Interview for DSM-V) in Schizophrenia in 63 participants. Completed in 23 May 2024.
23 May 2024
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 1 March 2021 |
| Primary completion | 23 May 2024 |
| Estimated completion | 23 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SCID (Standardized Clinical Interview for DSM-V)
- PSS (Perceived Stress Score)
- Urine Toxicology Screen
- Vitals
- Blood Work
- PQ-B
- COVID Screening
- Positive and Negative Syndrome Scale (PANSS)
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
- Schizophreniform Disorders — all drugs for Schizophreniform Disorders →
Sponsor
Stanford University
Who can join
Adults 18 to 40, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Peripheral complement C4 protein in schizophrenia: Association with gene copy number and immune cell subtypes.
Kalinowski A, Macaubas C, Guo H, Anker LA, et al · · 2026 · PMID 42113976 · DOI 10.1073/pnas.2536376123
Verify or expand the search:
- PubMed search for NCT05109065
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05109065 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109065.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing